RPTX | Repare Therapeutics Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.33 - 3.47
52 Week Range	2.7100 - 8.49
Beta	0.94
Implied Volatility	555.82%
IV Rank	46.66%
Day's Volume	112,615
Average Volume	111,628
Shares Outstanding	42,445,500
Market Cap	142,192,425
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-06-19

Valuation
Profitability
Growth
Health
P/E Ratio	-2.02
Forward P/E Ratio	N/A
EPS	-1.66
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	179
Country	Canada
Website	RPTX

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

RPTX's peers: ACCD, NRIX, MASS, RLAY, FUSN

*Chart delayed

Analyzing fundamentals for RPTX we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see RPTX Fundamentals page.

Watching at RPTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on RPTX Technicals page.